CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease, and cancer in 50,000 individuals.

Objective Cytochrome P450 (CYP) 1B1 enzymes metabolize tobacco-smoke polycyclic aromatic hydrocarbons and 17β-estradiol. CYP1B1*3 (rs1 056836 = Le u432V al = 4326C > G) and CYP1B1*4 (rs1800440=Asn453Ser=4390A>G) influence this metabolism. We, therefore, hypothesized that these two polymorphisms associate with risk of myocardial infarction (MI), ischemic heart disease (IHD), ischemic cerebrovascular disease (ICVD), chronic obstructive pulmonary disease (COPD), cancer overall, tobacco-related cancer, and female cancer, possibly dependent on tobacco exposure. Method We genotyped 10391 adults from the Copenhagen City Heart Study, who had been followed prospectively for more than 30 years. Significant results were retested cross-sectionally in the Copenhagen General Population Study (CGPS) with 37178 participants, and in the Copenhagen Ischemic Heart Disease Study with 2379 cases and 33 220 controls. Results In the Copenhagen City Heart Study, hazard ratio for MI among never smokers was 1.9 (95% confidence interval: 1.2-3.2) for CYP1 B1 * 3 GG (19%) versus CC (32%). These findings were, however, not confirmed when retested in CGPS and Copenhagen Ischemic Heart Disease Study. For tobacco-related cancer, we found decreasing risk with CYP1B1 * 3 CG and GG versus CC; however, this could not be confirmed in the CGPS. For IHD, ICVD, COPD, cancer overall, and female cancer, we found no association with CYP1 B1 * 3 genotype, overall or according to smoking status. For CYP1B1 * 4 genotype, we did not find any association with either endpoint, overall or according to smoking status. Conclusion CYP1B1 * 3 and CYP1B1 * 4 genotypes did not associate with the risk of MI, IHD, ICVD, COPD, cancer overall, tobacco-related cancer, or female cancer.